187 related articles for article (PubMed ID: 33474679)
1. Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+ breast cancer.
Mondaca JM; Guijarro ACC; Flamini MI; Sanchez AM
Breast Cancer Res Treat; 2021 Apr; 186(2):363-377. PubMed ID: 33474679
[TBL] [Abstract][Full Text] [Related]
2. Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+ Breast Cancer.
Castro-Guijarro AC; Sanchez AM; Flamini MI
Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686651
[TBL] [Abstract][Full Text] [Related]
3. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
4. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Nonagase Y; Yonesaka K; Kawakami H; Watanabe S; Haratani K; Takahama T; Takegawa N; Ueda H; Tanizaki J; Hayashi H; Yoshida T; Takeda M; Chiba Y; Tamura T; Nakagawa K; Tsurutani J
Oncotarget; 2016 Dec; 7(51):84860-84871. PubMed ID: 27768588
[TBL] [Abstract][Full Text] [Related]
5. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
Yamashita-Kashima Y; Shu S; Osada M; Fujimura T; Yoshiura S; Harada N; Yoshimura Y
Cancer Chemother Pharmacol; 2020 Nov; 86(5):641-654. PubMed ID: 32997196
[TBL] [Abstract][Full Text] [Related]
6. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
Baldassarre T; Truesdell P; Craig AW
Breast Cancer Res; 2017 Oct; 19(1):110. PubMed ID: 28974266
[TBL] [Abstract][Full Text] [Related]
7. STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.
Wang L; Wang Q; Gao M; Fu L; Li Y; Quan H; Lou L
Cancer Sci; 2018 Oct; 109(10):3305-3315. PubMed ID: 30076657
[TBL] [Abstract][Full Text] [Related]
8. Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.
Sabbaghi M; Gil-Gómez G; Guardia C; Servitja S; Arpí O; García-Alonso S; Menendez S; Arumi-Uria M; Serrano L; Salido M; Muntasell A; Martínez-García M; Zazo S; Chamizo C; González-Alonso P; Madoz-Gúrpide J; Eroles P; Arribas J; Tusquets I; Lluch A; Pandiella A; Rojo F; Rovira A; Albanell J
Clin Cancer Res; 2017 Nov; 23(22):7006-7019. PubMed ID: 28821558
[No Abstract] [Full Text] [Related]
9. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).
Diessner J; Bruttel V; Stein RG; Horn E; Häusler SF; Dietl J; Hönig A; Wischhusen J
Cell Death Dis; 2014 Mar; 5(3):e1149. PubMed ID: 24675467
[TBL] [Abstract][Full Text] [Related]
10. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase.
Adam L; Vadlamudi R; Kondapaka SB; Chernoff J; Mendelsohn J; Kumar R
J Biol Chem; 1998 Oct; 273(43):28238-46. PubMed ID: 9774445
[TBL] [Abstract][Full Text] [Related]
11. HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.
Sakai H; Tsurutani J; Iwasa T; Komoike Y; Sakai K; Nishio K; Nakagawa K
Breast Cancer; 2018 Sep; 25(5):605-613. PubMed ID: 29700710
[TBL] [Abstract][Full Text] [Related]
12. Hsp90 inhibition and co-incubation with pertuzumab induce internalization and degradation of trastuzumab: Implications for use of T-DM1.
Skeie M; Nikolaysen F; Chitano Y; Stang E
J Cell Mol Med; 2020 Sep; 24(17):10258-10262. PubMed ID: 32672902
[TBL] [Abstract][Full Text] [Related]
13. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
14. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
Gebhart G; Lamberts LE; Wimana Z; Garcia C; Emonts P; Ameye L; Stroobants S; Huizing M; Aftimos P; Tol J; Oyen WJ; Vugts DJ; Hoekstra OS; Schröder CP; Menke-van der Houven van Oordt CW; Guiot T; Brouwers AH; Awada A; de Vries EG; Flamen P
Ann Oncol; 2016 Apr; 27(4):619-24. PubMed ID: 26598545
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab emtansine: mechanisms of action and drug resistance.
Barok M; Joensuu H; Isola J
Breast Cancer Res; 2014 Mar; 16(2):209. PubMed ID: 24887180
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728.
Irie H; Kawabata R; Fujioka Y; Nakagawa F; Itadani H; Nagase H; Ito K; Uchida J; Ohkubo S; Matsuo K
Cancer Sci; 2020 Jun; 111(6):2123-2131. PubMed ID: 32248641
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of components of the focal adhesion complex by heregulin: role of phosphatase SHP-2.
Vadlamudi RK; Adam L; Nguyen D; Santos M; Kumar R
J Cell Physiol; 2002 Feb; 190(2):189-99. PubMed ID: 11807823
[TBL] [Abstract][Full Text] [Related]
19. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Baron JM; Boster BL; Barnett CM
J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
[TBL] [Abstract][Full Text] [Related]
20. The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer.
Delgado J; Vleminckx C; Sarac S; Sosa A; Bergh J; Giuliani R; Enzmann H; Pignatti F
ESMO Open; 2021 Apr; 6(2):100074. PubMed ID: 33647599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
